Pharmacokinetics of imidazole antimycotics.
According to data on the imidazole antimycotics at present on the market, none of these products satisfactorily fills the gaps which exist in the treatment for mycoses of internal organs, although they have brought considerable progress in the topical treatment of mycoses. On the basis of their very broad spectrum and high intensity of activity under suitable test conditions, and the comparatively tolerable amount of side effects in man, the present imidazole antimycotics are considered to be an encouraging start for future development of derivatives which will lead to products with considerably better pharmacokinetic, and therefore better therapeutic, properties.
D000328:Adult; D000818:Animals; D000935:Antifungal Agents / Q000378:metabolism* / Q000494:pharmacology; D002648:Child; D003022:Clotrimazole / Q000378:metabolism; D004464:Econazole / Q000378:metabolism; D005658:Fungi / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D008825:Miconazole / Q000378:metabolism; D011817:Rabbits; D013997:Time Factors
D000935:Antifungal Agents; D007093:Imidazoles; D004464:Econazole; D008825:Miconazole; D003022:Clotrimazole